TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Patrick W. Serruys
52749

REGISTER for free or LOG IN to view this content

We Recommend